Proprietary R&D

In-house R&D on development of novel platform technologies and drug discovery
In addition to providing R&D services to industrial clients, ACIES BIO also runs an internal R&D pipeline, aimed primarily at developing innovative technological platforms and processes for improved production of pharmaceutical drugs. These proprietary technology platforms can often be included in the scope of our R&D services to improve the efficiency of expression or production of a target metabolite.

a) Industrial heterologous expression systems for production of secondary metabolites and heterologous proteins / enzymes;

b) Advanced gene cloning tools for manipulation and efficient delivery of extremely large DNA fragments into expression hosts;

c) Drug discovery development of novel compounds focusing on anti-infective, anticancer, anti-inflammatory and neurodegenerative applications.

d) Innovative sustainable eco-bioprocesses

Acies was part of Bio World 2017, a unique forum for industry global leaders, policy makers and investors.  
The action is co-financed by the Republic of Slovenia and European Union from European Regional Development Fund.

More >>
Within public call "Enhancing innovation potential and competences in companies", Acies Bio was recognised as one of the innovative companies with best potential to contribute to international competitiveness of Slovenia through smart specialisation.

More >>